Trade Balance in Latvia
Latvia - Trade BalanceGDP growth moderated in annual terms in Q3, amid a broad-based slowdown and a less favorable base effect. Turning to the current quarter, high-frequency indicators paint an even less positive picture. Retail sales swung into contraction in October for the first time in eight months, which, coupled with November’s slightly higher unemployment rate and downbeat consumer sentiment, hints at weak private consumption in the quarter. Moreover, harmonized inflation hit its highest level since March 2009 in November, likely weighing further on private spending. Meanwhile, industrial output lost steam in October amid a fall in energy production. On a more positive note, after tougher restrictions led to a marked decline in Covid-19 cases, an uptick in the vaccination rate could help prevent an extension of the state of emergency which should end on 11 January.
Latvia - Trade Balance Data
|Trade Balance (USD billion)||-2.5||-2.1||-2.5||-2.7||-2.8|
5 years of economic forecasts for more than 30 economic indicators.
Latvia Trade Balance Chart
Source: Bank of Latvia and FocusEconomics calculations.
|Bond Yield||0.55||0.0 %||Jun 30|
|Exchange Rate||1.12||0.65 %||Dec 31|
Get a sample report showing our regional, country and commodities data and analysis.
Request a Trial
Start working with the reports used by the world’s major financial institutions, multinational enterprises & government agencies now. Click on the button below to get started.
December 8, 2021
Consumer prices increased 1.05 in November over the previous month, below October's 1.14% rise.
December 3, 2021
Industrial output rose 2.4% on a monthly basis in October, following September's 5.8% increase.
November 30, 2021
GDP growth moderated to 5.1% year-on-year in the third quarter from 10.8% in the second quarter, according to detailed national accounts data.
November 9, 2021
Consumer prices increased 1.14% in October over the previous month, accelerating from the 1.06% increase seen in September.
November 3, 2021
Industrial output expanded 5.8% year-on-year in September (August: +4.3% yoy).